AURIGENE ONCOLOGY LIMITED ANNOUNCES ENCOURAGING INITIAL DATA FROM 1ST TWO COHORTS OF PHASE 1 STUDY OF AUR112, AN ORAL SMALL MOLECULE INHIBITOR OF MALT1, IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

Reuters · 3d ago

Please log in to view news